Research
Hormonal
In the obesity-diabetes cohort, maridebart cafraglutide resulted in a mean percent change in body weight from baseline to week 52 ranging from -8.4% to -12.3%, compared to -1.7% with placebo.
Maridebart cafraglutide may also be effective for weight loss in individuals with obesity and type 2 diabetes.
StrongSupportsmedium confidence
In the obesity-diabetes cohort... the mean percent change in body weight from baseline to week 52... ranged from -8.4%... to -12.3%... with placebo.
Why this rating
Based on the phase 2, double-blind, randomized, placebo-controlled trial design.
Source
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
Ania M. Jastreboff et al. · New England Journal of Medicine · 2025
rct · n=592Cited 55×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →